Birch Pollen Allergy - Pipeline Review, Q2 2011

Global Markets Direct, May 2011, Pages: 39

Birch Pollen Allergy - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Birch Pollen Allergy - Pipeline Review, Q2 2011', provides an overview of the Birch Pollen Allergy therapeutic pipeline. This report provides information on the therapeutic development for Birch Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy. 'Birch Pollen Allergy - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Birch Pollen Allergy.
- A review of the Birch Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Birch Pollen Allergy pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Birch Pollen Allergy therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Birch Pollen Allergy Overview
Therapeutics Development
An Overview of Pipeline Products for Birch Pollen Allergy
Birch Pollen Allergy Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Birch Pollen Allergy Therapeutics - Products under Development by Companies
Companies Involved in Birch Pollen Allergy Therapeutics Development
ALK-Abello A/S
Allergy Therapeutics plc
Paladin Labs Inc.
Stallergenes S.A.
Allergopharma Joachim Ganzer KG
ImVisioN Therapeutics AG
Biomay AG
Birch Pollen Allergy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
rBet v1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Birch Pollen Allergoid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL0206st - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALK Birch Pollen Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IVN-Birch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TreeMATA MPL - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Birch Pollen Allergen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Staller - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Birch Pollen Allergen B-Cell Peptide Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Birch Allergen RNA Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Birch Pollen Allergy - Featured News
Apr 26, 2011: FDA To Lift Allergy Therapeutics INDs Clinical Hold For Three MATA-MPL Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Birch Pollen Allergy, Q2 2011
Products under Development for Birch Pollen Allergy – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
ALK-Abello A/S, 2011
Allergy Therapeutics plc, 2011
Paladin Labs Inc., 2011
Stallergenes S.A., 2011
Allergopharma Joachim Ganzer KG, 2011
ImVisioN Therapeutics AG, 2011
Biomay AG, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011

List of Figures
Number of Products under Development for Birch Pollen Allergy, Q2 2011
Products under Development for Birch Pollen Allergy – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Discovery and Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Customers who bought this item also bought

• Pollen Allergy - Pipeline Review, H2 2012
• Allergies - Pipeline Review, H2 2012
• Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2012
• Rhino-Conjunctivitis - Pipeline Review, H2 2012
• ImVisioN Therapeutics AG - Product Pipeline Review - 2012
• Conjunctivitis - Pipeline Review, H2 2012
• Allergic Rhino-Conjunctivitis - Pipeline Review, Q2 2011
• Peanut Allergy - Pipeline Review, H2 2012
• Peanut Allergy – Pipeline Review, H1 2013
• Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2012